BioCryst Pharmaceuticals BCRX Effective Income Tax Rate Reconciliation, Percent

Effective Income Tax Rate Reconciliation, Percent at other companies

Century CommunitiesCCS

26.3%+1.0pp

HTF

Heartflow, Inc. Common StockHTFL

0%—

PopularBPOP

16%-4.2pp

Evolution Metals & Technologies Corp. EMAT

0%0.0pp

BeldenBDC

18.7%+2.4pp

ePlusPLUS

28.4%+0.4pp

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateContinuingOperations.

The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's effective income tax rate reconciliation, percent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's effective income tax rate reconciliation, percent?: BioCryst Pharmaceuticals (BCRX) reported effective income tax rate reconciliation, percent of $0 in Q4 2025.
How has BioCryst Pharmaceuticals's effective income tax rate reconciliation, percent changed year-over-year?: BioCryst Pharmaceuticals's effective income tax rate reconciliation, percent increased by 150.0% year-over-year, from -$0.01 to $0.